Levels Dx currently has three projects under development. The first project focuses on early diagnosis of the most common type of liver cancer: hepatocellular carcinoma (HCC). Together with the Leiden University Medical Center (LUMC) and the Erasmus Medical Center (EMC) Levels Dx identified several combinations of biomarkers that can detect early-stage HCC with more accuracy than the current clinical standard. To further validate these biomarkers, the company is working on the organization of new clinical trials with larger patient cohorts.

The company’s second project aims to establish a biomarker panel that can differentiate between bacterial and viral infections in a clinical setting. Similar to the first project, Levels Dx has identified combinations of biomarkers that can accurately diagnose whether a respiratory infection is of bacterial or viral origin. A new study is being organized with academic medical centers to validate these biomarkers in a larger cohort of patients.

The company’s third project involves the prediction of sepsis. In contrast to the two other projects, this project is at an earlier stage. Currently, a discovery study is being set up to identify biomarkers that can predict the onset of sepsis in patients.